Mostrar el registro sencillo del ítem

Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention

dc.contributor.authorBachurin S.O.
dc.contributor.authorGavrilova S.I.
dc.contributor.authorSamsonova A.
dc.contributor.authorBarreto G.E.
dc.contributor.authorAliev G.
dc.date.accessioned2020-09-02T22:12:35Z
dc.date.available2020-09-02T22:12:35Z
dc.date.issued2018
dc.identifier10.1016/j.phrs.2017.11.021
dc.identifier.citation129, , 216-226
dc.identifier.issn10436618
dc.identifier.urihttps://hdl.handle.net/20.500.12728/3664
dc.descriptionAlzheimer disease (AD) and related forms of dementia are among the main medical and social problems in the economically developed countries. It is connected with significant increase in human life span in these regions and with the absence of efficient medicines for treatment and prevention of such diseases. Lack of positive results in the developing of novel drugs for AD treatment stimulates special attention on problem of early diagnosis and drug discovery for pharmacotherapy on the very early stages of dementia, in particular, on mild cognitive impairments (MCI) due to AD. Here we review the state of art in the field of MCI diagnostics and analyze the data on the pharmacological agents developed for MCI treatment, which currently are in preclinical and clinical trials. The conclusion was made that only the agents that act on the very early pathogenetic stages of the disease, when the damage of cholinergic neurons is not observed, can be efficient for pharmacotherapeutic intervention of MCI. Therefore, the focused search and design of “disease-modifying” medicines should be accepted as the most (and may be the only) efficient strategy for treatment and prevention of MCI. © 2017
dc.language.isoen
dc.publisherAcademic Press
dc.subjectAlzheimer's disease
dc.subjectClinical trial and AD treatment
dc.subjectDisease-modifying drugs
dc.subjectMultitargeting compounds
dc.subjectNeurodegenerative disease
dc.subjectRepositioning of old drugs
dc.subjectABC transporter subfamily B
dc.subjectalicapistat
dc.subjectan 2
dc.subjectban 2401
dc.subjectbca 909
dc.subjectbosutinib
dc.subjectbrexanolone
dc.subjectdf 302
dc.subjectdonepezil
dc.subjectelenbecestat
dc.subjectgre 213
dc.subjectitanapraced
dc.subjectladostigil
dc.subjectlevetiracetam
dc.subjectly 2599666
dc.subjectly 3002813
dc.subjectmicroRNA
dc.subjectmontelukast
dc.subjectneuroprotective agent
dc.subjectnnz 2591
dc.subjectphenserine
dc.subjectpioglitazone
dc.subjectsar 228810
dc.subjectsuvn 502
dc.subjecttak 71
dc.subjecttesamorelin
dc.subjecttropisetron
dc.subjectue 2343
dc.subjectunclassified drug
dc.subjectunindexed drug
dc.subjectverubecestat
dc.subjectbiological marker
dc.subjectAlzheimer disease
dc.subjectcerebrospinal fluid analysis
dc.subjectcholinergic nerve cell
dc.subjectdisease course
dc.subjectdrug effect
dc.subjectdrug screening
dc.subjecthuman
dc.subjectmetabolomics
dc.subjectmild cognitive impairment
dc.subjectnerve cell lesion
dc.subjectnerve degeneration
dc.subjectneuroimaging
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjectReview
dc.subjectrisk factor
dc.subjectanimal
dc.subjectcognitive defect
dc.subjectmetabolism
dc.subjectAlzheimer Disease
dc.subjectAnimals
dc.subjectBiomarkers
dc.subjectCognitive Dysfunction
dc.subjectHumans
dc.titleMild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85035001509.pdf
Tamaño:
3.802Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem